We herein report the case of a 77-year-old woman who developed acute thrombocytopenia during the 23rd cycle of modified FOLFOX therapy. She developed a hypersensitivity reaction with nasal bleeding. The chemotherapy infusion was immediately discontinued. The patient's symptoms resolved with discontinuation of chemotherapy and the administration of supportive therapy. A complete blood count showed severe thrombocytopenia, and oxaliplatin-induced thrombocytopenia was diagnosed. The patient was admitted to the hospital, and the thrombocytopenia was corrected with a platelet transfusion followed by prednisolone. She was discharged after one week without requiring additional platelet transfusions. With the widespread use of oxaliplatin, the risk of oxaliplatin-induced acute thrombocytopenia should be considered an acute onset hematological emergency.
Introduction
Oxaliplatin is a third-generation platinum compound that inhibits DNA synthesis. Oxaliplatin is widely used to treat colorectal cancer (CRC) in the adjuvant and metastatic disease settings in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in a regimen known as FOLFOX. The major adverse effects associated with oxaliplatin are neurotoxicity, bone marrow suppression and gastrointestinal toxicity. However, hypersensitivity reactions accompanied by severe thrombocytopenia, a less frequent complication, can also occur (1) . We herein describe a case of a sudden-onset hypersensitivity reaction with severe thrombocytopenia following treatment with oxaliplatin (oxaliplatin-induced acute thrombocytopenia).
Case Report
A 77-year-old woman with CRC and no known allergic history who had previously undergone partial sigmoidectomy and colostomy was treated with modified FOLFOX (oxaliplatin: 85 mg/m 2 day 1, LV: 400 mg/m 2 day 1, 5-FU: 400 mg/m 2 as an intravenous bolus on day 1, followed by 2,400 mg/m 2 on day 1 infused over 46 hours) every two weeks as a second-line treatment. She tolerated this regimen well and her disease remained stable for over 15 months. During the 23rd cycle of chemotherapy, approximately 15 minutes into a planned 2-hour infusion of oxaliplatin and LV, she developed a hypersensitivity reaction with chills, fever and hypertension. The chemotherapy infusion was immediately discontinued. The patient's symptoms gradually resolved with discontinuation of the chemotherapy and the administration of supportive therapy with oxygen, hydrocortisone (100 mg) and histamine H1-receptor blocker (hydroxyzine pamoate: 25 mg). However, the patient experienced epistaxis and developed petechial hemorrhage. She was taken to the emergency room for a close investigation.
On examination, the patient was found to have no active spontaneous bleeding; however, excessive oozing at the venipuncture site and widespread petechiae were observed. She was awake and alert, and her vital signs were as fol- Figure. Time course of the platelet counts and body temperature during the treatment of the patient. A rapid decrease in the platelet count was observed immediately after infusion of oxaliplatin. Oxaliplatin was discontinued and 10 units of platelet transfusion with prednisolone, meropenem and gabexate mesilate were administrated. The follow-up platelet count gradually increased without requiring additional platelet transfusions.
lows: blood pressure: 208/92 mmHg; pulse: 88 beats per minute; temperature: 39.3°C; and oxygen saturation: 96% on ambient air. Although the WBC count, RBC count and hemoglobin level did not show any remarkable changes (7,080/μL to 8,300/μL, 332×10 4 /μL to 333×10 4 /μL and 9.6 g/dL to 9.8 g/dL, respectively), the patient's platelet count had dropped from 253,000/μL to 3,000/μL during chemotherapy. Because severe thrombocytopenia occurred within an extremely short time span, oxaliplatin-induced acute thrombocytopenia was clinically diagnosed. The patient was admitted for stabilization, and the thrombocytopenia was corrected with a platelet transfusion followed by intravenous prednisolone administration (1 mg/kg). Initially, she received gabexate mesilate with broad-spectrum antibiotics (meropenem 3 g/day) for suspected disseminate intravenous coagulation (DIC) related to sepsis; however, these medications were stopped based on almost normal coagulation study results and negative results of a blood culture. Because there were no findings of red cell fragmentation on the patient's peripheral blood smear and her renal function, bilirubin, haptoglobin and lactate dehydrogenase results were almost normal, the possibility of hemolysis, including thrombotic thrombocytopenic purpura (TTP), was unlikely. The next day, the patient's platelet count increased to 68,000/μL with resolution of bleeding. A follow-up blood count showed an increased platelet count, reaching nearly normal levels, and the patient was discharged after one week of observation ( Figure) .
Discussion
Although the major dose-limiting side effect of oxaliplatin is neurotoxicity, grades 3 to 4 thrombocytopenia are found in 3-4% of patients exposed to oxaliplatin (1) . The primary cause of oxaliplatin-related thrombocytopenia is bone marrow suppression, similar to that observed with other anticancer drugs. However, two novel major mechanisms of oxaliplatin-related thrombocytopenia have been recently reported (2, 3). One mechanism involves oxaliplatin-induced thrombocytopenia, while the other involves splenic sequestration of platelets due to portal hypertension related to sinusoidal injury. Because oxaliplatin-induced acute thrombocytopenia occurs abruptly and is sometimes life-threatening, appropriate therapy should be provided. To the best of our knowledge, 23 cases of oxaliplatin-induced acute thrombocytopenia have been reported (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The frequency of oxaliplatin-induced acute thrombocytopenia is unknown; however, the occurrence rate is probably underestimated because complete blood counts are not routinely performed in patients without severe allergic symptoms or bleeding tendencies. The characteristics of patients diagnosed with oxaliplatin-induced acute thrombocytopenia, including our patient, are summarized in Table. Similar to our case, previous reports (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) have shown that the onset of oxaliplatininduced acute thrombocytopenia is relatively rapid and most affected patients are women (75%) with an average age of 59.8 years (range: 38-83 years). The average number of cycles of onset of thrombocytopenia is 17.3 (range: 9-24 cycles), and all but one case (96%) occurred after 10 cycles of chemotherapy, which suggests that female sex and prolonged exposure to oxaliplatin are risk factors for the development of this reaction. The average platelet count at onset is 17,000 / μL, and various symptoms such as chills (6, 7, 12, 18), fever (7), skin rashes (6, 18), abdominal or back pain (5, 9, 11, 12) , nausea (13, 21) , dizziness (21), mental status changes (13) and bronchospasm (18) are experienced, with the exception of bleeding tendencies. Because oxaliplatin-induced acute thrombocytopenia does not always accompany a bleeding tendency at the time of initial presentation, physicians need to pay careful attention and initiate blood testing for thrombocytopenia to manage patients with unexplained symptoms who receive oxaliplatin. The fact that hypersensitivity reactions have been found to frequently precede manifestations of thrombocytopenia in previous studies as well as in our case is noteworthy. Thrombocytopenia leading to clinical bleeding typically occurs within several hours, although it sometimes occurs up to a few days (9, 21) . The symptoms sometimes mimic DIC related to severe infection or TTP in the acute phase, and conducting microscopic examinations of peripheral blood smears, coagulation tests and adequate culture studies for possible sepsis is necessary, especially in patients that develop im-mune hemolytic anemia (4, 5, 7, 8, 11, 12, 17, 21) . Regarding treatment, the platelet counts gradually increase with discontinuation of oxaliplatin; however, the majority of cases (83%) require platelet transfusions during the acute phase. Although sufficient evidence of effectiveness has not been provided, corticosteroids were used in almost half the reported cases (52%). This therapy is reasonable because oxaliplatin-induced acute thrombocytopenia, especially that related to immune thrombocytopenia, is related to the development of oxaliplatin-dependent antibodies against the glycoprotein IIb/IIIa complex (8, 9, 17, 18) . The exact mechanisms underlying oxaliplatin-induced acute thrombocytopenia are not completely understood; however, current hypotheses suggest that such antibodies naturally occur and can increase the strength of their interaction in the prolonged presence of oxaliplatin, resulting in platelet destruction and thrombocytopenia (2) . With adequate therapy, all but one patient (96%) recovered.
Because the clinical manifestations in our case were characterized by the sudden development of thrombocytopenia with a hypersensitivity reaction, the following explanations are proposed: 1) immune-mediated (antibody-mediated) destruction of platelets; 2) destruction of platelets due to systemic inflammatory reactions (immune or non-immune); 3) DIC especially related to sepsis; and 4) drug-induced TTP. As described above, the findings of no abnormal coagulation study results and negative results of blood culture indicate that DIC related to sepsis was unlikely. Furthermore, no findings of red cell fragmentation with almost normal results of biochemical tests are inconsistent with TTP. Therefore, although tests for specific platelet-bound antibodies were not performed, we believe that immune-mediated thrombocytopenia is the most likely explanation. In addition, the timing and rapidity with which the thrombocytopenia developed is also highly suggestive of an immune-mediated cause. The clinical symptoms occurred in approximately 15 minutes in our case. This relatively early onset suggests that this phenomenon is caused by sensitization or antibodies induced during previous exposure to the drug (9) . In the present case, the patient experienced a severe hypersensitivity reaction characterized by chills, fever and hypertension simultaneously with acute thrombocytopenia. Several previous cases have reported similar allergic symptoms related to thrombocytopenia (6, 7, 11, 12, 18) . However, it is unknown whether hypersensitivity reactions, possibly resulting from a massive release of inflammatory cytokines, can induce destruction of platelets. Such a mechanism cannot be fully excluded in the present case. Further issues that require investigation include to what extent an increase in the cytokine levels can induce thrombocytopenia and whether this is associated with immune-mediated thrombocytopenia. Oxaliplatin was identified as the most likely causative factor because the acute reaction occurred during the oxaliplatin infusion. Moreover, these preceding symptoms imply that physicians should be cautious of oxaliplatin-related hypersensitivity reactions because they suggest a greater possibility for subsequent severe thrombocytopenia (11, 18) . This case and our literature review provide several important findings for the management of oxaliplatin-induced acute thrombocytopenia. First, providing a prompt diagnosis and treatment is essential to achieve good outcomes. Because definitive laboratory examinations for detecting specific antibodies to oxaliplatin are not usually available in the initial stage of oxaliplatin-induced acute thrombocytopenia, clinical judgment should be used and prompt action should be taken to prevent accidental death. Second, clinicians should pay attention to oxaliplatin-induced acute thrombocytopenia, especially in women with a history of over 10 cycles of use of oxaliplatin. Third, oxaliplatin-induced acute thrombocytopenia occurs with various symptoms (sometimes occurring without bleeding tendencies, especially in patients with hypersensitivity symptoms) and various timing of development (from one hour in the earliest stage to a few days in the latest stage). Therefore, it is imperative that patients be carefully examined for signs of possible thrombocytopenia, even after resolution of hypersensitivity reactions. Finally, with the widespread use of oxaliplatin in outpatient settings, it is important to consider the possibility of oxaliplatin-induced acute thrombocytopenia, acute onset and severe hematological emergencies, even for nonmedical oncologists.
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